Jolt Health Inc
Canadian Securities Exchange:JOLTView on OTC Pink - Current Information

  • LAST PRICE
    0.0050
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0050/ 2,082
  • Ask / Lots
    0.0100/ 1,714
  • Open / Previous Close
    0.0000 / 0.0050
  • Day Range
    ---
  • 52 Week Range
    0.0050
    0.0250
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 6, 2024

      Show headlines and story abstract

    • 5:25PM ET on Monday May 06, 2024 by Accesswire
      Companies Mentioned: JTHTF

      FDA Approved and Viability to Address Underserved Lupus, Rheumatoid Arthritis and Malaria market, forecast to be worth $6 Billion USD by 2027*

      VANCOUVER, BC / ACCESSWIRE / May 6, 2024 / Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT)(FSE:G1Q0) is pleased to announce an arms-length agreement dated April 16, 2024 to acquire intellectual property to develop transdermal delivery technology for chloroquine and hydroxychloroquine that will add to its health and wellness portfolio with significant biotechnology assets.

Peers Headlines